Atai Life Sciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Srini Rao
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 31.7% |
| CEO tenure | no data |
| CEO ownership | 0.07% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Psychedelic Stock Deep Dive: Atai Life Sciences
Sep 03Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$129m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$550k | -US$40m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$145m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$4m | US$550k | -US$152m |
| Sep 30 2022 | n/a | n/a | -US$196m |
| Jun 30 2022 | n/a | n/a | -US$194m |
| Mar 31 2022 | n/a | n/a | -US$205m |
| Dec 31 2021 | US$12m | US$481k | -US$168m |
| Sep 30 2021 | n/a | n/a | -US$166m |
| Jun 30 2021 | n/a | n/a | -US$218m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$3m | US$400k | -US$170m |
Compensation vs Market: Srini's total compensation ($USD1.73M) is about average for companies of similar size in the US market ($USD1.42M).
Compensation vs Earnings: Srini's compensation has been consistent with company performance over the past year.
CEO
Srini Rao (55 yo)
no data
Tenure
US$1,734,650
Compensation
Dr. Srinivas G. Rao, M.D., Ph D., also known as Srini, serves as Chief Executive Officer at Atai Life Sciences N.V. since January 01, 2025 and had been its Co-Chief Executive Officer since June 01, 2024 De...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Supervisory Board | no data | US$158.96k | 2.48% $ 6.2m | |
| Co-Founder & CEO | no data | US$1.73m | 0.070% $ 175.3k | |
| Chief Financial Officer | 1.3yrs | US$1.17m | 0.044% $ 110.4k | |
| Chief Operating Officer | no data | no data | no data | |
| Vice President of Investment & Venture Management | 4yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | 0.014% $ 34.5k | |
| Senior VP | 4yrs | no data | no data | |
| Chief Business Officer | 2.2yrs | no data | 0.038% $ 96.3k | |
| Chief Medical Officer | 1.3yrs | no data | no data |
1.3yrs
Average Tenure
46yo
Average Age
Experienced Management: ATAI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Supervisory Board | 4yrs | US$158.96k | 2.48% $ 6.2m | |
| Independent Member of Supervisory Board | 4yrs | US$151.96k | 0% $ 0 | |
| Independent Supervisory Director | less than a year | no data | no data | |
| Independent Member of Supervisory Board | 4yrs | US$140.46k | 0.0028% $ 7.0k | |
| Independent Supervisory Director | less than a year | no data | no data | |
| Independent Member of Supervisory Board | 4yrs | US$150.46k | 0.0028% $ 7.0k | |
| Independent Lead Member of Supervisory Board | 4yrs | US$158.96k | 0.31% $ 786.5k |
4.0yrs
Average Tenure
57yo
Average Age
Experienced Board: ATAI's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:51 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |